The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Connecticut for 2023. There is no shortage of reasons for why Connecticut has a flourishing healthcare sector these days. The Nutmeg State, while small, boasts a high concentration of top-ranked hospitals and medical centers, renowned academic institutions that drive healthcare technology research and advancements, and a well-developed healthcare infrastructure that ensures access to quality care for residents. This thriving ecosystem creates abundant prospects for healthcare technology companies to innovate and make meaningful advancements within the field. The individuals recognized on this year's list have played a pivotal role in guiding these companies towards not just financial success, but also transformative breakthroughs that have the power to positively impact lives.
Among the distinguished honorees in this year's list, we have Wayde McMillan, who has been serving as Chief Financial Officer and Treasurer for Insulet Corporation since March 2019. An industry veteran, McMillan has a long track record of success, including serving as CFO for the Minimally Invasive Therapies Group at Medtronic, where he oversaw a business generating $8 billion in revenue, with a global workforce of over 20,000 employees. On the other hand, Vlad Coric, the CEO of Biohaven, has guided his company's remarkable growth from approximately $6 million to a sale totaling $13 billion. Additionally, Michael Urban, Chief Information Officer of Framework Solutions, manages technology solutions that support his company's operations and enhance security and efficiency. Among his many career achievements, Urban previously played a significant role in the technology design and implementation of the $26.5 million Medical Care Center project.
Please join us in celebrating The Top 25 Healthcare Technology Leaders of Connecticut for 2023.
1. Bryan Hanson
Company: Zimmer Biomet
Title: Chairman, President and Chief Executive Officer
Bryan C. Hanson is the President and CEO of Zimmer Biomet, a global medical technology company that utilizes data analytics and AI to develop innovative products and digital solutions that enhance mobility and improve health outcomes for patients. Hanson joined the company in December 2017. Today he also serves as a member of the Board of Directors.
Prior to his role at Zimmer Biomet, Hanson held executive positions at Medtronic and Covidien. At Medtronic, he served on the Executive Committee and was the EVP and Group President of the Minimally Invasive Therapies Group. At Covidien, he was the Group President with global responsibility for all business segments. He also held leadership roles including Group President of Medical Devices & U.S., President of Energy-based Devices, and Group President of Surgical Solutions. He started his career at Covidien in 1992. Hanson holds a Bachelor of Science in finance from Florida State University. Additionally, he has completed executive education programs at the Kellogg School of Management and Harvard University.
On top of his current role at Zimmer Biomet, Hanson serves on the board of directors of Walgreens Boots Alliance – and is a member of the compensation and leadership performance committee, as well as the finance and technology committee. He is also a board member of the Advanced Medical Technology Association; and chairs the China subcommittee. Furthermore, Hanson serves as a director emeritus of the Americares board of directors, an organization focused on emergency response and global health initiatives.
2. Andrew McKillop
Company: Pfizer
Title: Senior Vice President, Pharmaceutical Sciences Small Molecules
Andrew McKillop is the Senior Vice President of Pharmaceutical Sciences Small Molecules at Pfizer, one of the world's largest research-based pharmaceutical companies. Founded in 1849, the pharma giant is focused in areas where it believes it can have the greatest impact on patients and society, pursuing innovative biopharmaceutical therapies and vaccines across a wide range of diseases and conditions. Its mission is to deliver breakthroughs that change patients’ lives.
McKillop leads a group of researchers that take small-molecule discoveries and design the manufacturing processes to obtain the active pharmaceutical ingredient and the dosage form to enable the product to reach patients across the globe. Many of Pfizer’s recognizable medicines have been developed by McKillop’s group, with the most recent example being PaxlovidTM, the first FDA-approved oral treatment for COVID.
McKillop holds a PhD in analytical chemistry from Loughborough University and a BS in chemistry from the University of Sheffield, both in the United Kingdom.
3. Matthew Cohen
Company: Medtronic
Title: Vice President, Research And Development
Matthew Cohen is the Vice President of Research and Development for Medtronic's Minimally Invasive Technologies Group. With almost 26 years of experience in the medical device industry, Cohen has been dedicated to developing innovative technologies, particularly in surgical areas such as minimally invasive laparoscopy, intelligent instrumentation, biodegradable implants, and wound closure devices.
Notably, Medtronic is a global leader in healthcare technology, committed to addressing complex health issues through groundbreaking solutions. With a mission to alleviate pain, restore health, and extend life, Medtronic operates in 150 countries and boasts a team of over 90,000 dedicated individuals.
Cohen began his career in 1998 as a manager of manufacturing engineering at US Surgical. He then worked at Tyco, before progressing to the role of VP of R&D Surgical Solutions at COVIDIEN, his previous position prior to joining Medtronic. Cohen earned a Bachelor of Science in Electrical Engineering from the University of Hartford, where he currently serves as Vice Chairman of CETA's Board of Visitors. He is also a member of the CBIT Executive Board at Yale University and the UConn Venture and Investment Advisory Board, including the Technology Innovation Program (TIP). Among his many accomplishments, Cohen holds 15 U.S. patents, with multiple patents still pending.
4. Wayde McMillan
Company: Insulet
Title: EVP and Chief Financial Officer
Wayde McMillan has been serving as the Executive Vice President, Chief Financial Officer and Treasurer for Insulet Corporation since March 2019. Insulet, headquartered in Massachusetts, is a pioneering medical device company focused on simplifying the lives of individuals with diabetes and other medical conditions through its Omnipod product platform.
Prior to joining Insulet, McMillan held the position of CFO and VP of Finance for the Minimally Invasive Therapies Group at Medtronic. In this role, he oversaw a business generating $8 billion in revenue, with a workforce of over 20,000 employees, and a global finance team. McMillan also held several leadership positions at Covidien. These positions included CFO and VP of Finance for the Medical Devices Group & U.S., CFO and VP of Finance for the Surgical Solutions Business Unit, and VP of Finance and Controller for the Respiratory and Monitoring Solutions Business Unit. McMillan began his career in accounting, audit, financial analysis, and investor relations roles at various organizations.
McMillan holds a Bachelor of Science in business administration from Merrimack College and an MBA from Bentley University's McCallum Graduate School of Business.
5. Matthew Sulzicki
Company: Optum
Title: Vice President of Partnerships & Analytics
Matthew Sulzicki is the Vice President of Partnerships and Analytics at Optum, a health services and innovation provider. The company is on a mission to help people live healthier lives, while also helping to make the health system work better for everyone. Optum, part of the UnitedHealth Group family of businesses, empowers modern health care by connecting and serving the whole health system across 150 countries. It combines cutting-edge technology, the world’s largest health care database, and vast expertise to improve health care delivery, quality, and efficiency. Optum is revolutionizing health care that serves more than 100,000 physicians, practices, and other health care facilities – as well as 127 million individual consumers.
Before joining Optum, Sulzicki was a senior healthcare economics analyst at UnitedHealthcare. Before that, he served as a lecturer of economics at the University of New Hampshire. Sulzicki graduated from the University of New Hampshire with an MA in economics, from Auburn University with an MS in economics, and from the University of Connecticut with an undergraduate degree in economics.
6. Vlad Coric
Company: Biohaven Limited
Title: CEO and Chairman Board of Directors
Vlad Coric has served as the CEO of Biohaven for over seven years, leading the company from a start-up to a publicly traded company listed on the New York Stock Exchange. Under his leadership, Biohaven experienced significant growth, with the company's valuation increasing from approximately $6 million to a sale totaling $13 billion. Coric's focus has been on advancing novel medications to underserved patients. During his tenure, he has successfully guided the company through its first FDA approval and the launch of Nurtec® ODT, an acute treatment for migraine.
With more than 20 years of experience in drug discovery and clinical development, Coric previously worked at Yale School of Medicine and Bristol-Myers Squibb. He has expertise across various therapeutic areas, including neuroscience, virology, oncology, and immuno-oncology. Throughout his career, Coric has been involved in multiple drug development programs, contributing to the development of drugs such as Nurtec ODT, zavegepant, Abilify®, Opdivo®, Yervoy®, Daklinza®, and Sunvepra®.
In addition to his role at Biohaven, Coric continues to serve as an Associate Clinical Professor of Psychiatry at Yale School of Medicine since July 2001. Over the years, he has held various positions within the Yale medical community, including inpatient chief of the Yale Clinical Neuroscience Research Unit and director of the Yale Obsessive-Compulsive Disorder Research Clinic. Coric has also served as president of the Connecticut Psychiatric Society and has authored numerous peer-reviewed publications. He completed his internship at Yale-New Haven Hospital and his residency training at the Yale Psychiatry Residency Training Program. Coric earned his medical degree from Wake Forest University School of Medicine and holds a Bachelor of Science in neurobiology and physiology from the University of Connecticut, where he was an honors scholar.
7. John Houston
Company: Arvinas
Title: Chairperson, President, and CEO
John Houston holds the positions of Chairperson, President, and Chief Executive Officer for Arvinas, a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins to improve the lives of patients with debilitating and life-threatening diseases.
With over 30 years of experience, Houston previously served as the Senior Vice President of Specialty Discovery at Bristol Myers Squibb (BMS). During his tenure of more than 18 years at BMS, he held various roles of increasing responsibility. He was accountable for all Discovery Biology disease teams and led multiple Discovery technology departments. Houston was also a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee, which provided governance oversight in the discovery space.
Before joining Bristol Myers Squibb, Houston worked at Glaxo Wellcome Research and Development in the UK, where he served as the head of the Lead Discovery Unit. Currently, he serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics, and BioCT. Houston earned his BS in medical microbiology from Glasgow University and his PhD in microbial biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant at Glasgow University.
John Houston Insight
"I am honored to be recognized as one of the Top 25 Healthcare Technology Leaders of Connecticut for 2023. I feel incredibly lucky to work alongside dedicated, passionate, and talented colleagues who make up Team Arvinas, and this acknowledgment would not be possible without them. It is a privilege to be among such accomplished professionals who are shaping the future of healthcare technology. We remain committed to advancing innovation, improving patient outcomes, and transforming the healthcare landscape.”
8. Julie Dixon
Company: Takeda
Title: Vice President, Head Global Regulatory Affairs, Oncology
Julie Dixon is the Head of Global Regulatory Affairs for the Oncology Business Unit at Takeda, the largest pharmaceutical company in Asia. She joined the company in January 2021 and is responsible for partnering with teams to develop and execute innovative regulatory strategies that enable the development and commercialization of life-changing therapies for patients. Founded over two centuries ago, Takeda aims to discover and deliver life-transforming treatments in their core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Dixon brings more than 20 years of pharmaceutical experience, encompassing drug discovery experience through integrating regulatory strategy into drug development and precision medicine. Prior to joining Takeda, Dixon spent several years at Bristol Myers Squibb, where she held multiple roles of increasing responsibility, including Global Regulatory Head of Cardiovascular, and Global Regulatory Head of Early Assets Oncology and Precision Medicine.
Before joining BMS, Dixon held research and regulatory strategy positions at Bayer HealthCare Pharmaceuticals. She was a global regulatory lead in the areas of cardiovascular and diagnostic imaging; and was a medicinal chemist and project leader, responsible for oncology research programs. Dixon holds a PhD in synthetic organic chemistry from the University of Illinois, Urbana-Champaign. She later conducted post-doctoral research studies at Yale University. She also holds a BS in chemistry from the University of Michigan.
9. Peter Malyak
Company: Natera, Inc.
Title: Vice President of US Reproductive Health Sales
Peter Malyak began his professional career 35 years ago. Today, he is the Vice President US Reproductive Health Sales of Natera, Inc. His company is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Its aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health – and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, Natera sets out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.
Malyak first got his start in 1988 as a regional sales manager at Abbott Labs. From there, he went on to Eli Lilly, before eventually rising to national strategic sales director at LipoScience, his most recent position prior to joining Natera. Malyak graduated from Canisius College with an undergraduate degree in physical education and athletic training.
Natera Insight
"Natera's cell-free DNA technology is transforming disease management across women's health, oncology and organ health. We are excited to be driving the application of precision medicine to address critical unmet needs, provide both patients and physicians with the tools they need to improve care management, and partner with esteemed health institutions to lead the way across powerful dimensions of healthcare."
10. Brian Meltzer
Company: Alexion Pharmaceuticals
Title: Vice President, Global Medicine Leader
Brian Meltzer is the Vice President and Global Medicine Leader at Alexion Pharmaceuticals. In this role, he leads global, multidisciplinary teams in achieving clinical, regulatory, and commercial success for rare diseases. Meltzer initially joined Alexion as an Executive Director of Global Program Team Leader, focusing on Wilson Disease. His company is dedicated to transforming the lives of individuals affected by rare diseases and devastating conditions – through the development and delivery of innovative medicines, as well as supportive technologies and healthcare services.
Prior to joining Alexion, Meltzer held various positions in the pharmaceutical and healthcare industry. He served as an Executive Director of Clinical Development at Adare Pharmaceuticals, Chief Medical Officer and VP of Business Development at Perseon, and Head of Licensing & Business Development at Purdue Pharma. Additionally, he worked as a Commercial Leader of Clinical Innovations at Ortho Clinical Diagnostics. Earlier in his career, Meltzer was a Medical Director at the Urgent Care Center of Memorial Sloan-Kettering Cancer Center.
Meltzer holds an MBA in healthcare administration from Baruch College and an MD from the State University of New York Upstate Medical University. He completed his undergraduate degree in biomedical science at The City College of New York.
11. Jeffrey Finman
Company: Cognitive Research
Title: SVP, Chief of Biostatistics
Jeffrey Finman is Senior Vice President, Chief of Biostatistics at Cognitive Research Corporation, a full-service CRO that specializes in Central Nervous System product development. Its mission is to support innovative companies developing new medicines and therapies to improve mental health and neurological disorders. As a leading neuroscience clinical research organization (CRO) and cognitive assessment technology company, CRC works with sponsors, specialized clinical trial sites, and CNS experts to bring new drugs through rigorous testing to support FDA submissions and eventual market introduction. CRC adds value using proprietary patient evaluation tools CRCDS MINISIM (the only driving simulator validated for use in multi-site clinical trials) and COGSCREEN (its exclusive, validated computer-administered and scored neuropsychological test battery designed to rapidly assess deficits or change across a range of cognitive functions). CRC is well-positioned to conduct clinical studies at any stage of product development.
Finman got his start in 1985 as a clinical statistician at Pfizer, where he spent 24 years earning additional leadership responsibilities. In 2009 he founded Jupiter Point Pharma Consulting, a firm providing statistical input for drug development programs – including the design, analysis, interpretation, and defense of clinical trials in support of regulatory submission. The firm was acquired by Cognitive Research Corporation in 2022.
Finman earned a PhD in biostatistics from the Medical College of Virginia/Virginia Commonwealth University School of Medicine and a BS in statistics from the State University of New York at Oneonta.
12. John McBride
Company: Parexel
Title: Vice President, Client Delivery
John McBride began his professional career 15 years ago. Today, he is the Vice President of Client Delivery at Parexel, which is among the world’s largest clinical research organizations. Parexel provides a full range of (Phase I to IV) clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of their clinical, regulatory and therapeutic expertise, their team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators, and sites to design and deliver clinical trials with patients in mind.
McBride began his career in 2008 as a project manager of post approval at INC Research. He graduated from the University of Connecticut with a PharmD.
13. Marianne Ruscz
Company: PharMerica
Title: Vice President of Operations
Marianne Ruscz currently holds the position of Vice President of Operations at PharMerica. Her journey with the company began when she joined as a staff pharmacist immediately after completing her education. At a young age, her interest in the field was piqued by an early exposure to long-term care pharmacy through the experience of having her elderly grandparents living with her; and observing her mother's work in a skilled nursing facility as a director of nursing.
Notably, PharMerica is a leading provider of pharmacy services, catering to institutional, community-based, and home-based settings. The company serves various markets including long-term care, senior living, hospitals, home infusion, hospice, behavioral health, specialty, and oncology pharmacy. PharMerica operates a network of over 180 pharmacies specializing in long-term care, home infusion, and specialty services across all 50 states.
Throughout her tenure at PharMerica, Ruscz has consistently held leadership positions. Within a year of joining the company, she was promoted to the role of Pharmacy Director. Over time, she continued to advance and eventually became the Regional Pharmacy Director overseeing operations in the New England area. Ruscz holds an MBA and a master's in healthcare from Capella University. She also obtained her undergraduate degree in Pharmacy from Duquesne University.
14. Josh Bilenker
Company: Treeline Biosciences
Title: CEO and Co-Founder
Josh Bilenker is the Chief Executive Officer and Co-Founder of Treeline Biosciences, a biotech company focused on developing precision medicines for patients with cancer and other serious conditions. Additionally, he serves as a director of Gossamer Bio and Sana Biotechnology.
Before his involvement with Treeline, Bilenker served as the CEO of Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company. Bilenker joined Eli Lilly following its acquisition of Loxo Oncology, where he was the founding CEO. Prior to that, he worked as a life sciences venture capital investor at Aisling Capital. He also served as a medical officer in the Office of Oncology at the U.S. Food and Drug Administration from August 2004 to April 2006
Bilenker received his medical training at the University of Pennsylvania, specializing in internal medicine and medical oncology – and obtaining board certification in these disciplines. He holds an MD from The Johns Hopkins University School of Medicine and an AB in English, summa cum laude, from Princeton University.
15. Greg Russo
Company: Intuitive
Title: Vice President of Finance and Product Operations
Greg Russo began his professional career 22 years ago. Today, he is the Vice President of Finance and Product Operations of Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Intuitive believes that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, the company expands the potential of physicians to heal without constraints.
Russo first got his start in 2001 as a senior financial analyst at GE Capital Real Estate. He graduated from the University of Connecticut School of Business with an MBA in international business and finance. He also graduated from Bentley University with an MS in finance.
16. Tony Listro
Company: Sever Pharma Solutions
Title: Vice President of Technology
Tony Listro is Vice President, Technology, and Site Lead of Sever Pharma Solutions’ Putnam, Connecticut site. Sever Pharma Solutions (SPS) is a Contract Development and Manufacturing Organization (CDMO) with manufacturing sites in Malmö, Sweden, and Putnam, Connecticut. The company partners with small to large-sized pharmaceutical and biotech companies to provide end-to-end solutions to develop, manufacture, and characterize Polymer-based dosage forms. This includes dosages based on HPAPIs. SPS has deep knowledge of polymer materials and process technologies. It utilizes extrusion technologies to enhance solubility of poorly water-soluble molecules; and to create implantable dosage forms.
Prior to joining SPS, Listro held various business and technical leadership roles with Foster Delivery Science and Foster Corporation in Putnam, Connecticut. He developed various drug products including oral and implantable dosage forms for more than 15 years. Listro earned his BS and MS in Plastics Engineering from the University of Massachusetts in Lowell. He also earned an MBA from the University of Massachusetts in Amherst. Among his many accomplishments, he holds 2 U.S.-issued patents; and has authored and/or co-authored 20 publications.
17. AJ Pace
Company: Defibtech
Title: Vice President of Global Marketing
AJ Pace is the Vice President of Global Marketing at Defibtech, a company known for its innovative automated external defibrillators (AEDs) and life-saving resuscitation products. Defibtech utilizes advanced design and manufacturing techniques to produce high-quality, reliable, and user-friendly solutions in the field of cardiac resuscitation. Their product portfolio includes the Lifeline™ and ReviveR™ families of AEDs, as well as accessories such as the Lifeline ARM automated chest compression device.
Pace has a long history with Defibtech, joining the company in 2003 as a Shipping & Receiving Specialist. Over the years, he has taken on various roles within the organization, including Product Manager and Director of Manufacturing. Pace's dedication and contributions to the company led to his appointments as Vice President of Manufacturing and Vice President of Corporate Development, before assuming his current position as Vice President of Global Marketing. Pace holds an undergraduate degree in marketing from Southern Connecticut State University.
AJ Pace Insight
“In the 20 years I’ve been with Defibtech, I’ve watched the company grow from a start-up into an internationally recognized organization. Our life-saving mission is the same, but it’s been incredibly rewarding watching our impact expand with the help of our parent company, Nihon Kohden Corporation. The kind of success we’ve seen can only happen when you have an amazing, hardworking, and dedicated team, and I’m honored to be a part of it."
18. Todd Rearick
Company: Quantum-Si
Title: Chief Technology Officer
Todd Rearick has been serving as the Chief Technology Officer (CTO) of Quantum-Si since January 2019. Quantum-Si is a well-funded venture that provides an empowering environment for individuals to tackle complex problems and drive groundbreaking scientific advancements. The company is focused on innovation, development, and bringing revolutionary products to market.
Before joining Quantum-Si, Rearick held the position of CTO at Hyperfine Research and Engineering Fellow at Life Technologies. Before that, he worked as a Principal Engineer for Ion Torrent, a company specializing in DNA sequencing technologies. Rearick's lengthy career also includes working as a Software Manager at Raindance Technologies – and various roles at Sycamore Networks, a telecommunications equipment manufacturer. He began his career at the Naval Undersea Warfare Center in New London, Connecticut. Rearick earned his Bachelor of Science in Engineering Science from Penn State University.
19. Michael Urban
Company: Framework Solutions
Title: Chief Information Officer
Michael Urban joined Framework Solutions in 2021 as the Chief Information Officer. In this role, he is responsible for implementing and managing technology solutions that support the company's operations and enhance security and efficiency. Framework Solutions specializes in offering comprehensive Clinical to Commercial Solutions for Biotechnology and Pharmaceutical companies. Notably, Framework provides strategic and tactical solutions in areas such as Medical Affairs, Regulatory, MLR, and Commercialization – supported by their Technology Group that offers tech-enabled solutions and integrated enterprise help desk/infrastructure support.
Before joining Framework, Urban accumulated 25 years of experience in Information Technology, primarily in the healthcare industry. As the Director of IT at Bristol Health, he focused on off-campus expansion, relocation, and consolidation projects. This includes the integration of multiple medical specialty practices. Among his many accomplishments, he played a significant role in the technology design and implementation of the $26.5 million Medical Care Center project.
Prior to his time at Bristol Health, Urban served as Vice President and Chief Information Officer at VitalWorks. There, he designed, implemented, and supported a national wide-area network that connected nine regional facilities and provided systems and operational support to over 750 users. Earlier in his career, he held the position of Director of IT and Client Services at Micro-Designs Software.
20. Christopher Galusha
Company: Emergent BioSolutions
Title: Vice President of Enterprise Business Applications
Christopher Galusha is the Vice President of Enterprise Business Applications of Emergent BioSolutions. His company develops, manufactures, and delivers protections against public health threats. For more than two decades, Emergent has been at work defending people from things they hope will never happen — so that they’re prepared, just in case they ever do.
Before joining Emergent, Galusha was an executive director of lead business partner for global operations and finance at Alexion Pharmaceuticals. Before that, he served as a director of application support at Accenture. Galusha graduated from Cameron School of Business at UNC Wilmington with a master's in accounting.
21. Shanna Deng
Company: CooperSurgical
Title: Vice President of Global Marketing
Shanna Deng began her professional career more than 22 years ago. Today, she is CooperSurgical’s Vice President of Global Marketing. CooperSurgical is driven to advance the care of women, babies, and families around the world. It believes in empowering individuals and healthcare professionals in making health and life choices. Notably, CooperSurgical is trusted by clinicians worldwide for products, technologies, and services that support a wide range of reproductive solutions: from contraception to fertility, and preventative, and therapeutic gynecological care.
Deng began her career in 2001 as an associate director of alumni affairs for the upstate NY regional office at Cornell University. From there, she went on to Pfizer Consumer Healthcare, before eventually rising to VP of global marketing at Cell Signaling Technology, her most recent position prior to joining CooperSurgical. Deng graduated from the University of Virginia Darden School of Business with an MBA and from Cornell University with an undergraduate in anthropology and Spanish.
22. John Krawczynski
Company: LGC Clinical Diagnostics
Title: SVP, Finance
John Krawczynski joined LGC Clinical Diagnostics in September 2019 as Senior Vice President, Finance. His company, LGC Clinical Diagnostics, develops and manufactures a comprehensive portfolio of catalog and custom-developed diagnostic quality solutions, biological and reagent component materials for the extended life sciences industry.
Krawczynski has over 25 years of experience working in accounting and finance with publicly held and private equity owned companies – as well as within a Big 4 public accounting firm. His most recent work experience includes serving as Senior Director Corporate Finance at KVH Industries; Chief Accounting Officer and Corporate Controller at Rogers Corporation; and Vice President Finance, Controller at The Yankee Candle Company.
Krawczynski holds a BS in business administration from Western New England University. From the same university, he also holds a Certificate in computer information systems. Notably, Krawczynski is a Certified Public Accountant. On top of his current LGC Clinical Diagnostics duties, he is a member of the Board of Directors and Chair of the Audit and Finance Committee at the Cambridge Credit Counseling Corporation. Furthermore, he serves as a member of the Board of Advisors of the Western New England University College of Business.
23. Frank Yocca
Company: BioXcel Therapeutics
Title: Chief Scientific Officer
Frank Yocca is a Chief Scientific Officer at BioXcel Therapeutics, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Founded in 2017, the company has been public since March 2018.
Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high performance, world-class teams in drug discovery and development. Under his leadership, the efforts of his teams have resulted in a number of prominent neuroscience products including Buspar®, Serzone® Abilify® and Heltioz®.
Previously, Yocca held leadership roles at AstraZeneca and Bristol Myers Squibb. As a recognized scientific leader in the neuroscience community, he serves as a member of the Institute of Medicine of the National Academy of Science; and a Fellow of the American College of Neuropsychopharmacology. Among his numerous accomplishments, he holds 45 referred articles, 96 abstracts, and 65 invited presentations. Yocca received a BS in biochemistry from Manhattan College. He also received his MS in pharmacology and PhD in neuropharmacology from St. John’s University.
24. Tom Greco
Company: Everly Health
Title: Vice President, Head of Channel Partnerships
Tom Greco began his professional career 20 years ago. Today, he is the Vice President and Head of Channel Partnerships at Everly Health. Launched in 2015, Everly Health was formed to improve the lives of millions with a fully integrated digital care platform for consumers and businesses. It continues to innovate in the space by delivering more care to more people on a seamless diagnostics-driven platform.
Greco first got his start in 2003 as a pharmaceutical sales representative at Boehringer Ingelheim Pharmaceuticals. From there, he went on to Matria Healthcare, before eventually rising to VP of portfolio development at Aspira Women's Health, his most recent position prior to joining Everly Health. Greco graduated from the University of New Haven with an MBA. He also graduated from the University of Vermont with an undergraduate degree.
25. Will Dolan
Company: Seres Therapeutics
Title: Vice President of Corporate Strategy
Will Dolan is the Vice President of Corporate Strategy at Seres Therapeutics. He first joined the company in 2021. Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products – novel drugs to treat diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres Therapeutics is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome.
Previously, Dolan was an executive director of corporate strategy office at Merck. Before that, he served as a senior director of enterprise strategy at Aetna. Earlier in his career, he worked with McKinsey & Company as an associate. Dolan earned a PhD in biology from UC San Diego. He also holds an undergraduate degree in biology from Massachusetts Institute of Technology.
